Form 4: CRISPR Therapeutics CFO Sells Shares to Cover Tax Obligations After RSU Vesting

Chief Financial Officer of CRISPR Therapeutics, Raju Prasad, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• On March 14, 2024, Raju Prasad, the CFO of CRISPR Therapeutics, had 10,000 restricted stock units (RSUs) vest.
• To cover the tax withholding obligation associated with the vesting of these RSUs, Mr. Prasad sold 3,524 common shares on March 15, 2024, at a price of $72.69 per share.
• The sale was mandated by the company's RSU Settlement Policy and wasn't a discretionary trade.
• Following the reported transactions, Mr. Prasad directly owns 6,476 common shares.
• Mr. Prasad also directly owns 30,000 restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine transaction related to executive compensation and tax obligations, and it doesn't indicate any significant positive or negative sentiment towards the company.

Industry Context

Sales of shares to cover tax obligations after RSU vesting are a common practice among company executives. This transaction is a routine part of executive compensation and doesn't necessarily reflect a change in the executive's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units (RSUs) that vest over time.
• Upon vesting, these RSUs are subject to income tax, and executives often sell a portion of the shares to cover these tax obligations.
• This practice is common across various industries and is not unique to CRISPR Therapeutics.
• Comparable companies in the biotechnology sector, such as Intellia Therapeutics and Editas Medicine, also have similar RSU programs for their executives.

Key Dates